CareDx Inc. announced recent drug development collaborations with three leading cell therapy biopharmaceutical companies to use CareDx's AlloCell surveillance in the respective companies' ongoing CAR T-cell therapy clinical studies. CareDx AlloCell is a highly sensitive, next-generation sequencing surveillance solution for patients who have received engineered or non-engineered allogeneic cell therapies for cancer or other autoimmune conditions. AlloCell is being used in several biopharmaceutical company clinical studies for investigational allogeneic CAR T-cell therapies in clinical development.

AlloCell assesses the cellular kinetics of allogeneic cellular therapies, such as the expansion and persistence of allogeneic cells, which may correlate with patients' response to treatment or adverse events. Allogeneic cell therapies represent a rapidly growing area of clinical research, with investigational therapeutics being evaluated in oncology, cardiovascular, neurological, autoimmune, and infectious diseases.